June 12, 2011
– Comments (5)
I "recommended" buying a few INSM shares in March 2011 in this post. It might be a good time to sell some of those now. There are currently 910 INSM shares in my "fund" (see here) with break-even of around 1.31 USD.
June 10, 2011 - 34th European Cystic Fibrosis Society (ECFS) Conference - A multi-cycle open-label study of nebulized liposomal amikacin (Arikace®) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
Poster #217 (pdf)
Poster #217 Presentation (pdf)
Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections
Portefeuille, I remember you saying at some point that someone on CAPS showed you how to embed images (as opposed to just links) in your blog posts. I am wondering if you would be so kind as to quickly enlighten me?
#3 It is described in comment #24 here.
It might be a good time to sell some of those now.
It might be a good time to buy them back now. INSM is currently at around $5.86.